CSL Behring is anticipated to sustain strong Ig demand and maintain momentum with HEMGENIX uptake and the global launch of ANDEMBRY. CSL Seqirus revenue is projected to benefit from the supply of ...

Investing.com -- Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B study, confirming the long-term efficacy and safety of ...